Form 8-K - Current report:
SEC Accession No. 0001193125-26-338009
Filing Date
2026-08-06
Accepted
2026-08-06 16:10:58
Documents
10
Period of Report
2026-08-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ctmx-20260806.htm   iXBRL 8-K 47013
2 EX-99.1 ctmx-ex99_1.htm EX-99.1 307139
  Complete submission text file 0001193125-26-338009.txt   477088

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ctmx-20260806.xsd EX-101.SCH 24832
13 EXTRACTED XBRL INSTANCE DOCUMENT ctmx-20260806_htm.xml XML 4725
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

EIN.: 273521219 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37587 | Film No.: 261249098
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)